The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Obturator Nerve Block with Botulinum Toxin Type B for Patient with Adductor Thigh Muscle Spasm -A Case Report-

  • Choi, Eun-Joo (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Byun, Jong-Min (Seoul National University College of Medicine) ;
  • Nahm, Francis Sahng-Un (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Lee, Pyung-Bok (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
  • Received : 2011.07.28
  • Accepted : 2011.08.05
  • Published : 2011.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

Obturator nerve block has been commonly used for pain management to prevent involuntary reflex of the adductor thigh muscles. One of several options for this block is chemical neurolysis. Neurolysis is done with chemical agents. Chemical agents used in the neurolysis of the obturator nerve have been alcohol, phenol, and botulinum toxin. In the current case, a patient with spasticity of the adductor thigh muscle due to cervical cord injury had obturator nerve neurolysis done with botulinum toxin type B (BoNT-B). Most of the previous studies have used BoNT-A with only a few reports that have used BoNT-B. BoNT-B has several advantages and disadvantages over BoNT-A. Thus, we report herein a patient who successfully received obturator nerve neurolysis using BoNT-B to treat adductor thigh muscle spasm.

Keywords

References

  1. O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002; 18(6 Suppl): S182-90. https://doi.org/10.1097/00002508-200211001-00011
  2. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75. https://doi.org/10.1016/j.jpainsymman.2004.05.002
  3. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005; 53: 3-9.
  4. Calderon-Gonzalez R, Calderon-Sepulveda RF. Clinical treatment (non surgical) of spasticity in cerebral palsy. Rev Neurol 2002; 34: 1-6.
  5. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.
  6. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-9. https://doi.org/10.1016/S0161-6420(80)35127-0
  7. Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des 2009; 15: 3671-80. https://doi.org/10.2174/138161209789271843
  8. Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol 2009; 10: 87-102. https://doi.org/10.2165/00128071-200910020-00002
  9. Kharkar S, Ambady P, Yedatore V, Schwartzman RJ. Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome. Pain Physician 2011; 14: 311-6.
  10. Lim SJ, Park HJ, Lee SH, Moon DE. Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-. Korean J Pain 2010; 23: 65-9. https://doi.org/10.3344/kjp.2010.23.1.65
  11. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003; 21: 476-80. https://doi.org/10.1016/j.clindermatol.2003.11.006
  12. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-9. https://doi.org/10.1212/01.wnl.0000183055.81056.5c
  13. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-7.
  14. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60. https://doi.org/10.1002/mds.20531
  15. Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 2004; 22: 23-8.
  16. Akkaya T, Unlu E, Alptekin A, Gumus HI, Umay E, Cakci A. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand 2010; 54: 79-85. https://doi.org/10.1111/j.1399-6576.2009.02130.x
  17. Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 2008; 326: 856-63. https://doi.org/10.1124/jpet.108.136242
  18. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62: 705-22. https://doi.org/10.2165/00003495-200262040-00011
  19. Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001; 20: 127-36. https://doi.org/10.1053/sder.2001.24421
  20. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-7. https://doi.org/10.1080/16501970510027312

Cited by

  1. Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome vol.10, pp.4, 2018, https://doi.org/10.3390/toxins10040164
  2. Long-Term Clinical Outcomes of War-Related Hip Disarticulation and Transpelvic Amputation : vol.95, pp.16, 2011, https://doi.org/10.2106/jbjs.l.01160
  3. A Morphometric Study of the Obturator Nerve around the Obturator Foramen vol.59, pp.3, 2016, https://doi.org/10.3340/jkns.2016.59.3.282